12/13/2011

Roche's Genentech unit reduced spending on journal ads for Avastin well before the FDA revoked approval for the drug to treat breast cancer. Genentech stopped promoting Avastin for breast cancer in August 2010 and reduced spending on journal ads for other indications in 2011, a spokeswoman said.

Related Summaries